A first-in-human Phase-I study conducted in Australia (The CARTELL Study, NHMRC identifier: 1102172) introduced PB into the clinics in 2016, used to manufacture CD19-specific CAR-T cells infused to patients suffering from relapsed/refractory CD19+ malignancies, namely B cell ALL and NHL. Here, CD19 is linked to non-Hodgkin lymphoma.